A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors - Concepedia

Concepedia

Publication | Open Access

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

DOI Full Paper Access

53

Citations

19

References

2012

Year

Gayle Jameson, John Hamm, Glen J. Weiss, Carlos Alemany, Stephen P. Anthony, M. Basche, Ramesh K. Ramanathan, Mitesh J. Borad, Raoul Tibes, Allen Lee Cohn,

Clinical Cancer Research

Abstract

Etirinotecan pegol showed substantial antitumor activity in patients with various solid tumors and a somewhat different safety profile compared with the irinotecan historical profile. The MTD recommended for phase II clinical trials is 145 mg/m(2) q14d or q21d.

References

	Year	Citations

Page 1